FDA Relaxes Regs For COVID-19 Mental Health Apps
With the increasing concern for people’s mental health as they cope with the COVID-19 crisis, the US agency has relaxed regulations for apps that are intended to treat disorders such as anxiety, depression and insomnia. Certain digital health products would not require a 510(k) clearance during the crisis to enter the market under an immediately-in-effect 15 April guidance document.
You may also be interested in...
The app allegedly shared sensitive customer information with three China-based data analysis and collection firms.
The temperature-detection devices are the latest target for enforcement policy guidance by the US agency, which says it will look the other way when it comes to regulatory compliance by makers of non-FDA-approved telethermographic systems.
Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.